PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
24475026-2	2014	METHODS AND RESULTS: Full platelet aggregation concentration response curves were generated in vitro to several platelet agonists in human plasma samples pretreated with rilapladib (selective Lp-PLA2 inhibitor) or vehicle.	rilapladib	170-180	phospholipase A2 group VII	Homo sapiens	192-199
23973698-0	2014	Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-positron emission tomography imaging.	rilapladib	38-48	phospholipase A2 group VII	Homo sapiens	52-91
32793181-8	2020	The result shows rilapladib is the only quinoline that can interrupt the Spike-RBD-ACE2 complex.	rilapladib	17-27	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	73-78
32793181-8	2020	The result shows rilapladib is the only quinoline that can interrupt the Spike-RBD-ACE2 complex.	rilapladib	17-27	angiotensin converting enzyme 2	Homo sapiens	83-87
29854933-1	2015	Background: The lipoprotein-associated phospholipase A2 inhibitor (Lp-PLA2), rilapladib (SB659032), is being evaluated as a potential treatment to slow the progression of Alzheimer"s disease (AD).	rilapladib	77-87	phospholipase A2 group VII	Homo sapiens	16-55
29854933-1	2015	Background: The lipoprotein-associated phospholipase A2 inhibitor (Lp-PLA2), rilapladib (SB659032), is being evaluated as a potential treatment to slow the progression of Alzheimer"s disease (AD).	rilapladib	77-87	phospholipase A2 group VII	Homo sapiens	67-74
29854933-1	2015	Background: The lipoprotein-associated phospholipase A2 inhibitor (Lp-PLA2), rilapladib (SB659032), is being evaluated as a potential treatment to slow the progression of Alzheimer"s disease (AD).	rilapladib	89-97	phospholipase A2 group VII	Homo sapiens	16-55
29854933-1	2015	Background: The lipoprotein-associated phospholipase A2 inhibitor (Lp-PLA2), rilapladib (SB659032), is being evaluated as a potential treatment to slow the progression of Alzheimer"s disease (AD).	rilapladib	89-97	phospholipase A2 group VII	Homo sapiens	67-74